| Literature DB >> 33762098 |
Abstract
Allogeneic transplantation remains the most definitive curative option for patients with acute myeloid leukemia (AML). However, given the median age of diagnosis of AML in the late 60s, patients and clinicians have been reluctant to offer transplant to many in the older population. In this age group, AML presents with higher risk molecular and cytogenetic phenotype and patients' comorbidities, performance status, frailty and life views all impact the decision-making about whether to proceed with transplantation. Recent analyses suggest promising outcomes and thus acknowledgement of chronological age should be tempered with assessments of performance status, frailty, donor availability and careful balancing of a patient's wishes, life goals and understanding of the risks before restricting access of older patients to the curative potential of allotransplantation.Entities:
Keywords: Age; Allogeneic transplant; Frailty; Non-relapse mortality
Mesh:
Year: 2021 PMID: 33762098 PMCID: PMC7994544 DOI: 10.1016/j.beha.2021.101243
Source DB: PubMed Journal: Best Pract Res Clin Haematol ISSN: 1521-6926 Impact factor: 3.020